US2005266554A1PendingUtilityA1
PDX1 expressing endoderm
Est. expiryApr 27, 2024(expired)· nominal 20-yr term from priority
C12N 5/0018C12Q 1/6881C12N 2502/13C12N 2506/02C12N 2501/115C12N 5/0606A61K 35/12C12N 2501/119C12N 15/1086C12N 2501/415C12N 2501/385C12N 5/0603C12N 2500/90C12N 2503/00C12N 2502/02C12N 2510/00C12N 2501/155C12N 5/0679C12N 5/0608C12Q 2600/158C12N 2501/16C12N 5/0676
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Claims
exact text as granted — not AI-modified1 . A cell culture comprising human cells, wherein at least about 2% of said human cells are pancreatic-duodenal homoebox factor-1 (PDX1) positive foregut endoderm cells, said PDX1-positive foregut endoderm cells being multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube.
2 . The cell culture of claim 1 , wherein at least about 5% of said human cells are PDX1-positive foregut endoderm cells.
3 . The cell culture of claim 1 , wherein at least about 10% of said human cells are PDX1-positive foregut endoderm cells.
4 . The cell culture of claim 1 , wherein at least about 25% of said human cells are PDX1-positive foregut endoderm cells.
5 . The cell culture of claim 1 , wherein human feeder cells are present in said culture, and wherein at least about 2% of human cells other than said human feeder cells are PDX1-positive foregut endoderm cells.
6 . The cell culture of claim 1 , wherein said PDX1-positive foregut endoderm cells express the homeobox A13 (HOXA13) gene.
7 . The cell culture of claim 1 , wherein said PDX1-positive foregut endoderm cells express the homeobox C6 (HOXC6) gene.
8 . The cell culture of claim 1 , wherein said PDX1-positive foregut endoderm cells express SOX17.
9 . The cell culture of claim 1 , wherein the expression of PDX1 is greater than the expression of a marker selected from the group consisting of alpha-fetoprotein (AFP), SOX7, SOX1, ZIC1 and NFM in said PDX1-positive foregut endoderm cells.
10 . The cell culture of claim 1 , wherein said cell culture is substantially free of cells selected from the group consisting of visceral endodermal cells, parietal endodermal cells and neural cells.
11 . The cell culture of claim 1 , wherein at least about 1 PDX1-positive foregut endoderm cell is present for about every 10 PDX1-negative definitive endoderm cells in said cell culture.
12 . The cell culture of claim 1 , wherein at least about 1 PDX1-positive foregut endoderm cell is present for about every 5 PDX1-negative definitive endoderm cells in said cell culture.
13 . The cell culture of claim 1 , wherein at least about 1 PDX1-positive foregut endoderm cell is present for about every 4 PDX1-negative definitive endoderm cells in said cell culture.
14 . The cell culture of claim 1 further comprising an embryonic stem cell.
15 . The cell culture of claim 14 , wherein said embryonic stem cell is derived from a tissue selected from the group consisting of the morula, the inner cell mass (ICM) of an embryo and the gonadal ridges of an embryo.
16 . The cell culture of claim 1 further comprising a retinoid.
17 . The cell culture of claim 16 , wherein said retinoid is retinoic acid (RA).
18 . The cell culture of claim 1 further comprising FGF-10.
19 . The cell culture of claim 1 further comprising B27.
20 . The cell culture of claim 1 further comprising both RA and FGF-10.
21 . The cell culture of claim 20 further comprising B27.
22 . A cell population comprising cells wherein at least about 90% of said cells are human PDX1-positive foregut endoderm cells, said PDX1-positive foregut endoderm cells being multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube.
23 . The cell population of claim 22 , wherein at least about 95% of said cells are PDX1-positive foregut endoderm cells.
24 . The cell population of claim 22 , wherein at least about 98% of said cells are PDX1-positive foregut endoderm cells.
25 . The cell population of claim 22 , wherein said PDX1-positive foregut endoderm cells express the HOXA13 gene.
26 . The cell population of claim 22 , wherein said PDX1-positive foregut endoderm cells express the HOXC6 gene.
27 . The cell population of claim 22 , wherein said PDX1-positive foregut endoderm cells express SOX17.
28 . The cell population of claim 22 , wherein the expression of PDX1 is greater than the expression of a marker selected from the group consisting of AFP, SOX7, SOX1, ZIC1 and NFM in said PDX1-positive foregut endoderm cells.Join the waitlist — get patent alerts
Track US2005266554A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.